课题基金 / 基金详情

PROGERIN ENDOTHELIAL DYSFUNCTION AND VASCULAR DISEASE

PROGERIN ENDOTHELIAL DYSFUNCTION AND VASCULAR DISEASE
早老素内皮功能障碍和血管疾病
批准号:
8514460
负责人:
MICHAEL A GIMBRONE
金额:
$29.98万
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-09-01 至 2015-05-31

项目摘要

项目成果

MICHAEL A GIMBRONE的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Vascular diseases, in particular atherosclerosis and its complications (e.g., myocardial infarction and stroke), continue to be a major public health problem that afflicts millions of people in the United States and other countries. Given their inherently complex and variable nature, the study of monogenic forms of some types of vascular disease (e.g., familial hyperlipidemias and atherosclerosis) can greatly assist in elucidating their pathogenesis. The recent discovery of the genetic basis of Hutchinson-Gilford Progeria Syndrome (HGPS) provides such an opportunity. HGPS is a premature aging disorder in which affected children have normal appearance at birth, but begin to age rapidly within 1-2 years. This disease affects multiple organ systems, including the heart and blood vessels. Indeed, the most prominent and fatal feature of HGPS is premature and accelerated atherosclerosis resulting in heart attacks and strokes. HGPS is caused by a single point mutation in the LMNA gene, which results in accumulation of a mutant form of the lamin A protein called Progerin. The central hypothesis of this project is that Progerin accumulation in vascular endothelium results in chronic endothelial dysfunction, contributing to the onset of vascular pathologies documented in patients with HGPS, and potentially also in normal individuals with aging. In the first specific aim, we will dissect the molecular pathways activated in Progerin-expressing cultured EC that lead to chronic endothelial dysfunction. In the second specific aim, we will elucidate the paracrine effects that endothelial-derived, Progerin- stimulated mediators (such as interleukin-1) exert on vascular smooth muscle cells. In the third specific aim, we will investigate the pathophysiological consequences of endothelial-specific expression of Progerin in vivo in a novel transgenic murine model. These studies should provide important mechanistic insights into the cellular and molecular causes of vascular disease in HGPS patients, and may suggest new therapeutic strategies for other vascular diseases in which endothelial dysfunction plays a pathogenic role. PUBLIC HEALTH RELEVANCE: Several human diseases are associated with aging; among these are atherosclerosis and its consequences, heart attacks and strokes. Children with a genetic mutation in a specific gene develop a syndrome of premature aging called Progeria. They develop atherosclerotic plaques, and are prone to heart attacks and strokes. We propose to understand how this mutation triggers the development of cardiovascular disease in children with Progeria. Results from these studies, involving a specific gene linked to the development of vascular disease, will hopefully indicate new ways to treat children with Progeria and may also lead to innovative strategies to diagnose, prevent, and treat heart disease in the general population.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
PROGERIN ENDOTHELIAL DYSFUNCTION AND VASCULAR DISEASE
  • 批准号:
    8318192
  • 项目类别:
  • 资助金额:
    $31.73万
  • 财政年份:
    2010
  • 负责人:
    MICHAEL A GIMBRONE
  • 依托单位:
PROGERIN ENDOTHELIAL DYSFUNCTION AND VASCULAR DISEASE
  • 批准号:
    8124991
  • 项目类别:
  • 资助金额:
    $31.72万
  • 财政年份:
    2010
  • 负责人:
    MICHAEL A GIMBRONE
  • 依托单位:
PROGERIN ENDOTHELIAL DYSFUNCTION AND VASCULAR DISEASE
  • 批准号:
    7784952
  • 项目类别:
  • 资助金额:
    $32.92万
  • 财政年份:
    2010
  • 负责人:
    MICHAEL A GIMBRONE
  • 依托单位:
Administrative
  • 批准号:
    7298281
  • 项目类别:
  • 资助金额:
    $28.1万
  • 财政年份:
    2005
  • 负责人:
    MICHAEL A GIMBRONE
  • 依托单位:
国内基金
海外基金
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
  • 批准号:
    JCZRQN202500010
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
  • 依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
  • 批准号:
    2025JJ70209
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
    雷芬芳
  • 依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
  • 批准号:
    --
  • 项目类别:
    面上项目
  • 资助金额:
    --
  • 批准年份:
    2024
  • 负责人:
    万荣
  • 依托单位: